Aberrant sialylation of glycoproteins has been detected in many tumors, and upregulation of the beta-galactosamide alpha-2,6-sialyltransferase 1 (ST6GAL1) has been implicated with tumor aggressiveness and chemoresistance in experimental models. In our present study, we aimed to study the prognostic or predictive role of ST6GAL1 in ovarian carcinoma, using two independent ovarian cancer cohorts. ST6GAL1 mRNA levels were retrieved from a publicly available database (n = 517), and ST6GAL1 protein levels were analyzed by western blot analysis in a cohort of 204 ovarian tumor samples. The results were correlated with clinical and histological tumor parameters and follow-up information. High ST6GAL1 mRNA levels significantly correlated with lymphovascular invasion and shorter survival, whereas high ST6GAL1 protein expression was associated with advanced stage, distant metastasis and shorter recurrence-free intervals. In both cohorts the prognostic role was most pronounced in tumors without macroscopically visible residual tumor after surgery. In these cases, ST6GAL1 expression levels might help to identify cases with a higher risk of chemoresistance and metastatic relapse that might require an adapted therapeutic regime.
Introduction
Aberrant glycosylation of cell surface proteins has been implicated in many different diseases and is mostly associated with a deregulated expression of glycosylation enzymes involved in O-or N-glycosylation. In cancer, there is an increasing evidence pointing to a role of glycosylation in tumor formation and metastasis (Oliveira-Ferrer et al. 2017) .
Beta-galactosamide alpha-2,6-sialyltranferase 1 (ST6GAL1) is a member of the family of sialyltransferases, which catalyze the transfer of sialic acids to terminal positions of carbohydrate groups of glycoproteins and glycolipids. During maturation of complex N-glycans, ST6GAL1 facilitates the transfer of sialic acid to terminal galactose residues with an α-2,6-linkage in the Golgi apparatus. ST6GAL1 upregulation has been found in numerous cancers where it was associated with changes in adhesion, migration, invasion, apoptosis evasion, dedifferentiation of cancer cells and poor prognosis for patients (Zhu et al. 2001; Park and Lee 2013) . Oversialylation of the receptors TNFR1, CD45 or EGFR by ST6GAL1 affected the apoptotic potential and chemoresistance in different cancer cell lines (Amano et al. 2003; Liu et al. 2011; Zhuo and Bellis 2011; Park and Lee 2013; Zhao et al. 2014; Ma et al. 2015; Chakraborty et al. 2018) . Moreover, ST6GAL1 expression correlated with the cancer stem cell markers ALDH1 and CD133 and was associated with stem cell properties suggesting that ST6GAL1 itself might be a cancer stem cell marker ). Besides, ST6GAL1 activity has been linked to radioresistance, since it can be induced by radiation treatment leading to increased cell survival, presumably by β1 integrin-mediated activation of the AKT pathway (Lee et al. 2010; Park and Lee 2013) .
Prior studies suggest that ST6GAL1 might also be relevant in ovarian cancer (OvCa). Compared to normal ovarian cells, OvCa cell lines show increased levels of a-2,6-sialylated N-glycans, accompanied by high ST6GAL1 transcript levels (Wang et al. 2005; Anugraham et al. 2014) . ST6GAL1 upregulation in OvCa was found both on mRNA level and by immunohistochemistry. However, no correlation was found with clinicopathological parameters, like stage, grade or CA125 levels (Wang et al. 2005; Swindall et al. 2013) . In an experimental study, sialylation of membrane-associated β1 integrin upon ST6GAL1 upregulation in OvCa cell lines resulted in increased adhesive and invasive potential of the cells, which is in line with a more metastatic phenotype (Christie et al. 2008 ). In addition, ST6GAL1 was shown to be involved in various apoptotic pathways: prolonged low-dose cisplatin treatment in OvCa cells resulted in the selection of resistant cells which showed higher ST6GAL1 expression . Hypersialylation of the Fas cell surface death receptor, i.e., by ST6GAL1, was shown to prevent the formation of the deathinducing signaling complex and apoptotic signaling .
In our own studies on the tumor suppressor activity of c-Fos in OvCa cells, we found a downregulation of ST6GAL1 in c-Fosoverexpressing cells in vitro and in vivo, adding information about transcriptional regulation of ST6GAL1 (Oliveira-Ferrer et al. 2014) . A first hint of a potential impact of ST6GAL1 on the survival of OvCa patients has been shown by Schultz et al. in a small cohort of 35 OvCa samples by immunohistochemistry analyses (Schultz et al. 2016) .
To our knowledge, so far no study on a large cohort has analyzed ST6GAL1 expression as a prognostic and predictive marker for clinical outcome in patients with OvCa. Therefore, we looked at the applicability of ST6GAL1 mRNA or protein expression as a prognostic marker for patient survival in two OvCa cohorts.
Results

ST6GAL1 mRNA levels in ovarian carcinomas (TCGA cohort)
In order to explore the role of ST6GAL1 mRNA levels in OvCa progression, we decided to analyze the microarray data of the TCGA (The Cancer Genome Atlas Research 2011) cohort. For this purpose, 536 CEL files generated from ovarian carcinomas had been downloaded. We excluded 16 duplicates and 3 cases with missing follow-up data, resulting in a cohort of 517 cases (Supplementary data, Table S1 ).
Among the expression data generated by Affymetrix chips, there were three probesets for ST6GAL1 (affymetrix no. 201998_at, 214970_s_at and 214971_s_at) . Since the mean expression levels for the latter probesets were extremely low (6.52 and 10.36), we concentrated on the probeset 201998_at showing a mean expression value of 446.61 (median 388.21).
By Chi-square tests using division into two groups (the 75th percentile cut-off), there was no significant association of ST6GAL1 expression with age at diagnosis, grading, clinical stage, residual disease after surgery and vascular invasion. Yet, there was a highly significant association of high ST6GAL1 mRNA levels with lymphovascular invasion (P = 0.001; Table I) In survival analysis, we could show a significantly shorter survival in carcinomas with high ST6GAL1 mRNA levels (P = 0.031; Figure 1A ). In stratified Kaplan-Meier analysis, this prognostic value was more clear-cut in the groups of stage III tumors (P = 0.0003) and in those without residual tumor nodules after surgery (P = 0.016; Figure 1B and C). In multivariate Cox regression analysis including the most important prognostic parameters for OvCa, residual tumor after surgery and clinical stage, ST6GAL1 turned out as an independent prognostic parameter for shorter survival in this tumor entity (P = 0.047; hazard ratio [HR] = 1.307; Table II ).
ST6GAL1 protein expression in ovarian carcinomas
ST6GAL1 protein expression was analyzed in 204 tumor samples from our clinic. Of these, 176 cases were from primary ovarian carcinomas, 12 samples from recurrent OvCa, 12 from tumors of low malignant potential (Borderline tumors) and 4 from benign cystadenomas. The characteristics of this cohort are given in Supplementary data, Table S2 . By western blot analysis, we observed a consistent signal around 50 kDa in the SKOV3 control whose intensity was set as 100%. In the ovarian tumor samples, we detected a signal at the same molecular weight of varying intensity with a mean expression level after densitometry of 412.7% in carcinomas (range 1.6-1438.5%; see Figure 2A ).
In comparison of tumors of different malignancy as well as primary and recurrent carcinomas, we observed a weak increase in ST6GAL1 protein expression from benign tumors to recurrent carcinomas ( Figure 2B ), but no significant differences in T-tests (not shown). Regarding the primary carcinomas, tumors with low ST6GAL1 expression (quartile 1) were compared statistically to those with moderate/high ST6GAL1 levels, which had been found to behave similarly. Chi-square tests revealed significant associations of ST6GAL1 expression with the presence of distant metastasis (P = 0.024) and advanced stage (P = 0.035), but no correlation with grade of differentiation, nodal involvement or residual tumor after surgery (Table III) . Moreover, by Pearson tests no correlations of ST6GAL1 protein expression with age of the patient, ascites amounts or CA125 serum levels before surgery were found (not shown). By Kaplan-Meier analysis, moderate/high ST6GAL1 expression was associated with a significantly shorter recurrence-free interval as compared to low ST6GAL1 protein levels (P = 0.038; Figure 2C ), whereas there was no difference in overall survival (not shown). The HR for recurrence in tumors with moderate/high ST6GAL1 levels was 1.62 (95% CI = 1.01-2.58). Stratified analysis revealed a more clear-cut prognostic value in tumors without distant metastasis (P = 0.049; not shown) and without residual tumor after surgery (P = 0.014; HR = 2.08, 95% CI = 1.14-3.79; Figure 2D ). In multivariate Cox regression analysis including ST6GAL1 expression, FIGO stage and residual tumor after surgery, ST6GAL1 lost its prognostic significance (not shown).
Discussion
For many proteins, the correct folding, transport, secretion, activity and stability depend on their correct glycosylation. The important role of this post-or co-translational process is demonstrated by the high number of >200 glycosylation proteins which catalyze the synthesis and attachment of O-and N-linked glycan structures in a precisely regulated way. It has long been known that tumor cells display an altered profile of cell surface glycans (Oliveira-Ferrer et al. 2017) ; however, the functional role of glycosylation in regulating tumor cell behavior remains poorly understood. One of the elevated glycan structures in cancer cells is α2-6-linked sialic acid, which is added to N-glycosylated proteins by the ST6Gal1 sialyltransferase.
High levels of ST6GAL1 have been associated with a more invasive and metastatic phenotype in various cancer types, for example, in colorectal and mammary cancer cell lines and in human anaplastic large cell lymphoma (Lin et al. 2002; Park and Lee 2013; Suzuki et al. 2015) . Christie et al. could extend these findings to OvCa cell lines, showing increased matrigel invasion upon forced ST6GAL1 expression (Christie et al. 2008) . They attributed their findings to the increased alpha-2-6 sialylation of integrin ß1 which consequently led to increased invasive potential, possibly through augmented adhesion to its ligand collagen 1. The present study provides evidence that these pro-invasive and pro-metastatic mechanisms also affect disease progression in vivo. Patients diagnosed with distant metastasis presented significantly higher ST6GAL1 protein levels. Regarding the mRNA data from the TCGA database, the dataset does not include information about distant metastasis. Yet, the significant correlation of high ST6GAL1 expression with lymphatic invasion of tumor cells and the trend toward increased vascular invasion point into the same direction.
Previous IHC and mRNA studies showed higher ST6GAL1 levels in OvCa tissues compared to matched normal Wang et al. 2005 ). Our present study did not reveal significant differences of ST6GAL1 expression in a comparison of groups with different malignant potential. Yet, further analysis of primary carcinomas on a protein level revealed significant associations with advanced stage and distant metastasis pointing to the upregulation of this enzyme during tumor progression. Kaplan-Meier analysis of the western blot data in this study could show that higher ST6GAL1 protein levels were significantly associated with a shorter recurrence-free survival (RFS) in OvCa, which is similar to prior results on clear-cell renal carcinoma (Liu et al. 2014) . Although it cannot be ruled out that a fraction of the measured ST6GAL1 mRNA or protein derived from stromal elements like immune cells, the majority doubtlessly was expressed in tumor cells which make up at least 70% of the cells in the extracted tissue samples.
In an experimental study on OvCa cells, high ST6GAL1 expression levels was associated with apoptosis evasion and chemoresistance to cisplatin treatment . In both cohorts of our present study, most patients were treated with a platinum-based chemotherapy. The significant association of high ST6GAL1 levels with earlier relapse in these cohorts offers new in vivo evidence of a role of this sialyltransferase in chemoresistance.
At present, the strongest prognostic parameter for primary OvCa is the success of debulking surgery: patients without macroscopically detectable residual tumor after radical surgery have a significantly longer RFS and OAS than those showing visible tumor residues. Interestingly, the prognostic significance of ST6GAL1 mRNA or protein expression in two independent cohorts is more clear-cut in patients with optimal debulking results without residual tumor. Obviously, increased sialylation does not confer an additional negative influence on tumor outcome in those cases with a very unfavorable prognosis due to incomplete tumor resection.
In patients with optimal debulking results, ST6GAL1 expression levels might help to identify cases with a higher risk of chemoresistance and metastatic relapse that might require an adapted therapeutic regime. Although there are no macroscopically visible tumor aggregates in these cases, floating tumor cells within the peritoneum cannot be totally removed and their chemosensitivity is crucial for tumor recurrence. In this context, the ability of the floating cells to form multicellular spheroids is decisive for their chemoresistance (Frankel et al. 1997; Schultz et al. 2016) . Glycosylation of key adhesion molecules, especially α2-6 sialylation, might impact spheroid formation, maintenance and in turn chemoresistance as well as adhesion of cancer cells at peritoneal surfaces. In line with this hypothesis, Schultz et al. could show that primary OvCa cells from ascites which had been sorted for ST6GAL1-mediated α2-6 sialylation grew as spheroids, while cells lacking α2-6 sialylation remained as single cells and lost viability (Schultz et al. 2016) .
As a prognostic or predictive marker in OvCa patients, detection of the ST6GAL1 protein or mRNA might be more practicable than quantification of the sialylation status of OvCa cellular glycoprotein as suggested before (Kuzmanov et al. 2013) . Moreover, this enzyme might be a promising therapeutic target, and blocking ST6GAL1 function might decrease metastasis formation due to its influence on hallmarks of the carcinogenic phenotype like adhesion, metastasis formation and chemoresistance. 
Materials and Methods
ST6GAL1 mRNA expression analysis
mRNA expression data for ST6GAL1 from serous ovarian adenocarcinomas were retrieved from The Cancer Genome Atlas (TCGA) Research Network. Patient annotation data and CEL files with scans of microarrays (microarray type Affymetrix HT HG U133A) were downloaded from TCGA (The Cancer Genome Atlas Research 2011) and jointly preprocessed in Affymetrix Expression console using the robust multiarray average method (Irizarry et al. 2003) . The characteristics of this cohort are given in Supplementary data, Table S1 .
For the statistical analysis of ST6GAL1 mRNA expression levels, all tumor cases were first divided into quartiles, then into two groups of quartiles 1-3 (lower 75%) and quartile 4 (upper 25%), representing low and high expression. Table S2 . Patients included in this retrospective study were treated between 1998 and 2012 and selected on the basis of tissue availability. Informed consent for the scientific use of tissue materials, which was approved by the local ethics committee (Ethik-Kommission der Ärztekammer Hamburg, #OB/V/03), was obtained from all patients. The study was performed in accordance to the principles of the declaration of Helsinki and REMARK criteria (McShane et al. 2006) . No radiotherapy, neoadjuvant chemotherapy or endocrine therapy had been administered before surgery.
Patient cohort for western blot analysis
Western blot analysis
Western blot analysis was performed as described previously (Mahner et al. 2008; Eckhoff et al. 2013) . Briefly, equal amounts of protein (20 μg) of each sample were loaded per well. The protein lysate from the cell line SKOV3 was used as a reference and internal control in all blots. After electrophoresis and blotting to PVDF membranes, ST6GAL1 was detected using goat anti-human ST6GAL1 antibody (AF5924, R&D Systems, Minneapolis, USA) at 1:1000 dilution over night at 4°C. Secondary antibody (mouse anti Goat, sc-2354, Santa Cruz Biotechnology Inc., Heidelberg, Germany) was incubated for 1 h at room temperature. Equal loading was verified by immunoblotting with β-actin antibody (sc-47778, Santa Cruz Biotechnology). After visualization by chemiluminescence reagent (SuperSignal West Pico kit, Pierce, Rockford, IL, USA) band intensities were quantified by densitometry (Imaging Densitometer GS-700, BioRad, Munich, Germany), calculated as percent intensity of the specific control sample and corrected according to actin expression.
For the statistical analysis, all tumor cases were first divided into four groups of similar size (quartiles Q1-Q4) representing low, moderate/low, moderate/strong and strong ST6GAL1 expression, then further combined to two groups with the 25% point as cut-off (quartiles Q1 vs. Q2-Q4).
Statistics
Statistical analysis was conducted using SPSS software Version 24 (IBM SPSS Statistics, Armonk, NY, USA). Chi-square tests were used to examine the correlations between ST6GAL1 mRNA or protein expression and clinicopathologic factors (age, FIGO stage, histology subtype, grading and residual postoperative tumor) as shown in Tables I and II . For prognostic parameters, the following groups were compared: histological grading (G1/G2 vs. G3), FIGO stage (I/II vs. III vs. IV), histological subtype (serous vs. others) and residual tumor (none vs. >1 cm). Survival curves were plotted by Kaplan-Meier analysis. Differences between survival curves were evaluated by Log-rank tests. Probability values (P-value) ≤ 0.05 were considered statistically significant.
Supplementary data
Supplementary data are available at Glycobiology online. 
